A novel method for capturing and quantifying urinary podocyte-derived migrasomes has been developed for the diagnosis of kidney disease (KD). This method, called WBFC (Wheat Germ Agglutinin-coated magnetic beads and flow cytometry), enables the efficient capture and quantification of migrasomes from bodily fluids such as urine, serum, and cell culture medium. The study found that the concentration of urinary podocyte-derived migrasomes was significantly higher in patients with KD and podocyte injury compared to healthy volunteers. These migrasomes were found to express abundant phospholipase A2 receptor (PLA2R) proteins, which could serve as a natural antigen for quantifying autoantibodies against PLA2R in the serum of patients with membranous nephropathy (MN). The WBFC method is user-friendly, efficient, and suitable for clinical application. It allows for the rapid and accurate detection of migrasomes, which could serve as a promising biomarker for the early diagnosis of KD with podocyte injury. The study also demonstrated that urinary migrasomes could serve as diagnostic biomarkers for various types of KD, including membranous nephropathy, diabetic nephropathy, focal segmental glomerulosclerosis, and lupus nephritis. The TSPAN4-migrasome signal was found to be a highly effective diagnostic marker for KD, with a high area under the curve (AUC) in ROC analysis. The study also showed that urinary migrasomes could distinguish between different types of KD and could detect podocyte injury even in the early stages of KD when other biomarkers were not yet elevated. The results suggest that urinary migrasomes have significant potential as a non-invasive diagnostic tool for KD.A novel method for capturing and quantifying urinary podocyte-derived migrasomes has been developed for the diagnosis of kidney disease (KD). This method, called WBFC (Wheat Germ Agglutinin-coated magnetic beads and flow cytometry), enables the efficient capture and quantification of migrasomes from bodily fluids such as urine, serum, and cell culture medium. The study found that the concentration of urinary podocyte-derived migrasomes was significantly higher in patients with KD and podocyte injury compared to healthy volunteers. These migrasomes were found to express abundant phospholipase A2 receptor (PLA2R) proteins, which could serve as a natural antigen for quantifying autoantibodies against PLA2R in the serum of patients with membranous nephropathy (MN). The WBFC method is user-friendly, efficient, and suitable for clinical application. It allows for the rapid and accurate detection of migrasomes, which could serve as a promising biomarker for the early diagnosis of KD with podocyte injury. The study also demonstrated that urinary migrasomes could serve as diagnostic biomarkers for various types of KD, including membranous nephropathy, diabetic nephropathy, focal segmental glomerulosclerosis, and lupus nephritis. The TSPAN4-migrasome signal was found to be a highly effective diagnostic marker for KD, with a high area under the curve (AUC) in ROC analysis. The study also showed that urinary migrasomes could distinguish between different types of KD and could detect podocyte injury even in the early stages of KD when other biomarkers were not yet elevated. The results suggest that urinary migrasomes have significant potential as a non-invasive diagnostic tool for KD.